Navigation Links
Amgen Announces Voting Results Of Annual Meeting Of Stockholders
Date:5/6/2009

THOUSAND OAKS, Calif., May 6 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN), today announced results of voting at the company's Annual Meeting of Stockholders, held at The St. Regis Hotel, San Francisco, Calif. Approximately 87.3 percent of outstanding shares were represented at the meeting.

The director nominees: David Baltimore, Frank J. Biondi, Jr., Francois de Carbonnel, Jerry D. Choate, Vance D. Coffman, Frederick W. Gluck, Frank C. Herringer, Gilbert S. Omenn, Judith C. Pelham, J. Paul Reason, Leonard D. Schaeffer and Kevin W. Sharer were each reelected to Amgen's Board of Directors, each receiving a majority of "For" votes of the votes cast. Each was elected by no less than 86.7 percent of the votes cast. With the reelection of these directors, Amgen currently has 12 directors.

With approximately 98.7 percent of "For" votes of the votes cast, stockholders ratified Ernst & Young LLP as Amgen's independent registered public accountants for the year ending Dec. 31, 2009.

Stockholders approved the Amgen 2009 Equity Incentive Plan, which authorizes the issuance of up to 100,000,000 shares of Amgen common stock. The proposal was approved with approximately 81.2 percent of votes cast "For."

Stockholders approved the proposed amendment to the company's Restated Certificate of Incorporation, as amended, to reduce the sixty-six and two-thirds percent (66-2/3%) voting requirement in the company's Restated Certificate of Incorporation, as amended, to a simple majority voting requirement for approval of certain business combinations. Approximately 84.4 percent of the outstanding shares of our common stock were in favor of the amendment.

Stockholders approved a nonbinding resolution recommending that the company amend its Amended and Restated Bylaws, as amended, to permit holders of 10 percent of the company's outstanding common stock the ability to call special meetings. The proposal received approximately 59.5 percent of the votes cast "For" the proposal. Stockholders rejected the proposal requesting that the company change its jurisdiction of incorporation from Delaware to North Dakota. The proposal received less than 3.2 percent of the votes cast "For" the proposal.

The final vote totals will be included in the company's second quarter periodic report to be filed with the Securities and Exchange Commission.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

    Contacts:
    Amgen, Thousand Oaks
    David Polk: 805-447-4613 (media)
    Arvind Sood: 805-447-1060 (investors)

(Logo: http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO)


'/>"/>
SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
2. Preclinical Data From Amgens Oncology Pipeline to be Presented at AACR
3. Amgen to Present at the Cowen and Company Annual Healthcare Conference
4. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
5. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
6. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
7. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
8. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
9. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
10. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
11. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology:
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):